{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:04:31Z","timestamp":1787015071691,"version":"build-2736575974"},"reference-count":54,"publisher":"Wiley","issue":"s457","license":[{"start":{"date-parts":[[2008,3,13]],"date-time":"2008-03-13T00:00:00Z","timestamp":1205366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Paediatrica"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anderson\u2013Fabry disease is an X\u2010linked lysosomal storage disorder resulting from deficiency of \u03b1\u2010galactosidase A. The subsequent accumulation of globotriaosylceramide (Gb\n                    <jats:sub>3<\/jats:sub>\n                    ) in cells and tissues of the body has multisystemic effects and significantly impacts upon quality of life and survival of individuals with this condition. In general, Anderson\u2013Fabry disease is more severe in male patients; however, despite X\u2010linkage, females may develop severe signs and symptoms of the disease, although there is considerable phenotypic heterogeneity, which correlates most closely with age. Histological analyses of biopsies have shown evidence of Gb\n                    <jats:sub>3<\/jats:sub>\n                    storage in the kidney and heart in female patients. Gb\n                    <jats:sub>3<\/jats:sub>\n                    levels are also elevated in the urine of females, although plasma Gb\n                    <jats:sub>3<\/jats:sub>\n                    levels are not reliably elevated. The efficacy of enzyme replacement therapy (ERT) with recombinant human \u03b1\u2010galactosidase A has been demonstrated in females in a clinical trial and in observational studies, including those using data from outcome surveys. Benefits include a reduction in left ventricular mass, stabilization of renal function and improvements in pain and quality of life.\n                  <\/jats:p>\n                  <jats:p>Conclusion: If early intervention with ERT in females is to be advocated, it is necessary to demonstrate not only that females with Anderson\u2013Fabry disease have clinical and biochemical features of \u03b1\u2010galactosidase A deficiency and respond to ERT, but also that early intervention prevents the onset of the later manifestations of the disorder. Any strategy for early therapy should also balance future advantages against any impact on quality of life.<\/jats:p>","DOI":"10.1111\/j.1651-2227.2008.00649.x","type":"journal-article","created":{"date-parts":[[2008,3,13]],"date-time":"2008-03-13T05:04:37Z","timestamp":1205384677000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Early therapeutic intervention in females with Fabry disease?"],"prefix":"10.1111","volume":"97","author":[{"given":"Derralynn A","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,13]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.167.3922.1268"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.750"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.769"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/318809"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-2-4"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10497"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200410000-00020"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.025791"},{"issue":"443","key":"e_1_2_9_12_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1651-2227.2003.tb00217.x","article-title":"Hearing improvement in patients with Fabry disease treated with agalsidase alfa","volume":"92","author":"Hajioff D","year":"2003","journal-title":"Acta Paediatr"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01424.x"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2005.04.009"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BOLI.0000037342.59612.69"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000598"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2007.00029.x"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2895"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2005.036327"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012993305223"},{"key":"e_1_2_9_22_2","unstructured":"Data on File 39.393 Shire HGT Danderyd Sweden ."},{"key":"e_1_2_9_23_2","unstructured":"National Institute for Health and Clinical Excellence.Appraising orphan drugs. Available from:http:\/\/www.nice.org.uk\/niceMedia\/pdf\/smt\/120705item4.pdf."},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/190372a0"},{"issue":"439","key":"e_1_2_9_25_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1651-2227.2002.tb03120.x","article-title":"X\u2010chromosome inactivation and human genetic disease","volume":"91","author":"Lyon MF","year":"2002","journal-title":"Acta Paediatr"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2006.tb02384.x"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2006.tb02383.x"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<420::AID-AJMG6>3.0.CO;2-Z"},{"key":"e_1_2_9_29_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000469190","article-title":"Fabry disease: molecular diagnosis of hemizygotes and heterozygotes","volume":"38","author":"Desnick RJ","year":"1987","journal-title":"Enzyme"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1006\/rwgn.2001.0443"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2006.tb02386.x"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-005-5263-4"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2005.tb02112.x"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.10.1139"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000178976.62537.6b"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000139847.74101.03"},{"key":"e_1_2_9_37_2","first-page":"660","article-title":"Postmortem diagnosis of Fabry disease in a female heterozygote leading to the detection of undiagnosed manifest disease in the family","volume":"138","author":"Hulkova H","year":"1999","journal-title":"Cas Lek Cesk"},{"key":"e_1_2_9_38_2","first-page":"e93","article-title":"A 67\u2010year\u2010old woman with chronic proteinuria. Focal segmental and global glomerulosclerosis with light microscopic and ultrastructural features consistent with Fabry disease","volume":"130","author":"Osunkoya AO","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"443","key":"e_1_2_9_39_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2003.tb00212.x","article-title":"Evolution of renal pathology in Fabry disease","volume":"92","author":"Sessa A","year":"2003","journal-title":"Acta Paediatr"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100002936"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67635-0"},{"key":"e_1_2_9_42_2","first-page":"295","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"Deegan P","year":"2006"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BOLI.0000005658.14563.77"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2004.00219.x"},{"key":"e_1_2_9_45_2","unstructured":"Data on File 39.324: Shire HGT Danderyd Sweden ."},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1299-3"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.4.347"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(98)00032-2"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(82)80262-X"},{"key":"e_1_2_9_50_2","first-page":"1","article-title":"Guidelines for the diagnosis and management of Anderson\u2013Fabry disease. Publications and statistics","author":"Hughes DA","year":"2005","journal-title":"Department of Health"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta10240"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015511908710"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015009210639"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000223545.63012.5a"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725030-00003"}],"container-title":["Acta Paediatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1651-2227.2008.00649.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1651-2227.2008.00649.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T13:25:56Z","timestamp":1708694756000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1651-2227.2008.00649.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,13]]},"references-count":54,"journal-issue":{"issue":"s457","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1651-2227.2008.00649.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1651-2227.2008.00649.x","archive":["Portico"],"relation":{},"ISSN":["0803-5253","1651-2227"],"issn-type":[{"value":"0803-5253","type":"print"},{"value":"1651-2227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,13]]},"assertion":[{"value":"2008-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}